Sanofi: raises annual EPS target
(CercleFinance.com) - Sanofi says it expects its 2024 business EPS to be stable at CER (constant exchange rates), rather than a low single digit fall at CER, thanks to accelerated execution of its transformation focused on its R&D portfolio.
Q2 EPS was up 4% (again at constant exchange rates) at E1.73, on sales of over E10.7bn, up 10.2%, notably driven by its flagship product Dupixent (+29.2%).
While vaccine sales fell by 4.8%, those of Opella (consumer health) rose by 9.6% with the acquisition of Qunol, while new pharmaceutical launches increased by 80.4%, boosted by Altuviiio, Nexviazyme, Rezurock and Sarclisa.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Q2 EPS was up 4% (again at constant exchange rates) at E1.73, on sales of over E10.7bn, up 10.2%, notably driven by its flagship product Dupixent (+29.2%).
While vaccine sales fell by 4.8%, those of Opella (consumer health) rose by 9.6% with the acquisition of Qunol, while new pharmaceutical launches increased by 80.4%, boosted by Altuviiio, Nexviazyme, Rezurock and Sarclisa.
Copyright (c) 2024 CercleFinance.com. All rights reserved.